Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jun;18(6):849-54.
doi: 10.1093/neuonc/now007. Epub 2016 Feb 21.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy

Eudocia Q Lee  1 , Alona Muzikansky  1 , Jan Drappatz  1 , Santosh Kesari  1 , Eric T Wong  1 , Camilo E Fadul  1 , David A Reardon  1 , Andrew D Norden  1 , Lakshmi Nayak  1 , Mikael L Rinne  1 , Brian M Alexander  1 , Nils D Arvold  1 , Lisa Doherty  1 , Jennifer Stefanik  1 , Debra LaFrankie  1 , Sandra F Ruland  1 , Julee Pulverenti  1 , Katrina H Smith  1 , Sarah C Gaffey  1 , Samantha Hammond  1 , Patrick Y Wen  1
Affiliations
Randomized Controlled Trial

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy

Eudocia Q Lee et al. Neuro Oncol. 2016 Jun.

Abstract

Background: Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.

Methods: Eligibility criteria included age ≥18 years, Karnofsky performance status ≥60, and grade 2-4 glioma undergoing RT to a total dose of 50-60 Gy. Patients were randomized 1:1 to armodafinil or placebo for 8 weeks beginning within 10 days of starting RT. Fatigue and QOL were assessed at baseline, day 22, day 43, and day 56 with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), the Functional Assessment of Cancer Therapy - General (FACT-G), the Brief Fatigue Inventory (BFI), and the Cancer Fatigue Scale (CFS). The primary aim was to detect a difference in the 42-day change in FACIT-F fatigue subscale between the 2 groups using a 2-sample Wilcoxon statistic.

Results: We enrolled 81 patients total (42 armodafinil and 39 placebo). Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI. Further analysis suggests no difference between the arms even after accounting for the potential bias of missing data. Treatment was well tolerated with few grade 3 or 4 toxicities.

Conclusions: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study. Further studies are needed to determine whether pharmacologic treatment improves fatigue in glioma patients undergoing RT.

Keywords: armodafinil; clinical trial; fatigue; glioblastoma; glioma.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Consort diagram.
See this image and copyright information in PMC

Comment in

References

    1. Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro Oncol. 2012;14(Suppl 4):iv65–iv72. - PMC - PubMed
    1. Lovely M, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae . Oncol Nurs Forum. 1999;26(5):921–925. - PubMed
    1. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment . Neuro Oncol. 2015;17(4):488–504. - PMC - PubMed
    1. Page BR, Shaw EG, Lu L et al. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol. 2015;17(10):1393–401. - PMC - PubMed
    1. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579. - PubMed

Publication types